Legend Star, the China-based venture capital arm of Legend Holdings, has closed its fifth renminbi-denominated fund with more than CNY 900m (USD 124m) in commitments.
As more institutional investors dip their toes into private equity for the first time, managers must understand their motivations. Frontier sovereign wealth funds are an enticing wildcard
DataCanvas, a China-based artificial intelligence-driven (AI) big data solutions provider, has raised CNY 300m (USD 41m) in a first tranche of Series D funding with strong support from investors with ties to national-level state-owned enterprises (SOEs).
US-based meat and processed food maker Tyson Foods has received preliminary bids from private equity firms including Trustar Capital, Bain Capital and BPEA EQT for its China poultry business, according to two sources familiar with the matter.
Hong Kong blockchain specialist CMCC Global has reached a first close on its latest financial technology and web3 fund, raising the full targeted amount of USD 100m.
Legend Capital and Oriza FoFs have led a CNY 600m (USD 81m) Series D round for Leadrive, a Shanghai-headquartered manufacturer of semiconductor power modules and motor control units used in electric vehicles (EVs).
MTR Lab, a technology and innovation arm of Hong Kong transport operator MTR, has teamed up with Gobi Partners to invest HKD 46.8m (USD 5.9m) in local sustainable construction start-up isBIM.
SuperOrdinary, a global consumer brands accelerator that operates out of Shanghai, New York, and Los Angeles, has raised USD 58m in Series B funding at a valuation of more than USD 800m.
Navis Capital Partners wants to raise as much as USD 1.3bn for its ninth Asia fund, which is being primed for a formal launch early in the new year.
Regulatory pressures are encouraging Chinese VC firms to end longstanding US affiliations, but the impact of impending legislation – even sight unseen – cuts deeper into investor sentiment on China
True Light Capital, a Singapore-based asset manager established by Temasek Holdings, has raised USD 3.3bn for a fund that invests in companies that have a nexus to or a major business relationship with Greater China.
Shanghai International Group (SIG) – acting through an assortment of investment units – has led a CNY 2bn (USD 273m) Series D round for Chinese artificial intelligence (AI) chip designer Enflame Technology.
DCM has promoted two Asia-based investment professionals – Kenichiro Hara and Fiona Huang, who focus on Japan and China, respectively – to partner.
Eastern Bell Capital has led a Series D round of more than CNY 300m (USD 41m) for Huimei Cloud Technology, a China-based provider of artificial intelligence-enabled (AI) software that helps doctors make clinical decisions.
Chinese consumer-focused venture capital firm Tiantu Capital has launched a Hong Kong IPO with a view to raising as much as HKD 1.9bn (USD 253m).
PAG has agreed to acquire Shanghai Xingyi Cinema Management from Hong Kong-listed property developer Seazen for about CNY 1.4bn (USD 187m).
Alibaba Group’s logistics unit has filed for an IPO in Hong Kong, potentially creating liquidity events for private equity backers such as Yunfeng Capital, Primavera Capital Group, and Princeville Global, as well as for GIC, Temasek Holdings, and Khazanah...
Matrix Partners China and HongShan (formerly Sequioa Capital China) have joined a USD 16m pre-Series B round for Qihan Biotech, a genome editing player active in human and agricultural therapies.
China-based drug developer Lynk Pharmaceuticals has closed a second tranche of Series C funding, taking the overall size of the round to CNY 322m (USD 44m).
GGV Capital’s Asia business will sever ties with the firm’s international operation – switching to separate partnerships and a distinct brand – as venture capital continues to feel the impact of the US and China’s conflicting technology agendas.
Hong Kong’s package of incentives for family offices is intended to redress a balance that has swung in favour of Singapore. Geopolitics is dampening its competitive advantages
Concord Healthcare Group, an onshore subsidiary of US-listed Chinese healthcare business Concord Medical, has filed for an IPO in Hong Kong.
Chinese pharmaceutical industry services provider Canton Biologics has completed a CNY 300m (USD 41m) Series C round led by state-owned SDIC Venture Capital.
Chinese private equity firm Hony Capital has filed to raise a special purpose acquisition company (SPAC) in Hong Kong, having previously failed to get traction with a similar structure in the US.